{
    "type": "ETP",
    "ucits": false,
    "replication_method": "physical",
    "leverage": true,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "complex_factors": [
        "Leverage",
        "Daily Compounding",
        "High Risk",
        "ETP Structure"
    ],
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Securities (ETP) designed to provide 3x the daily return of the iShares MSCI Taiwan ETF through direct ownership of the underlying ETF shares combined with margin borrowing (leverage factor 3). The replication method is physical, as the ETP invests directly in the underlying ETF shares and uses margin (borrowing) to amplify exposure, not derivatives or swaps. There is no use of synthetic replication, swaps, or derivative instruments as part of the investment strategy. However, the product is highly leveraged (3x), with daily rebalancing and compounding effects that can cause returns over periods longer than one day to deviate significantly from 3x the underlying ETF's return. The product carries a highest risk rating of 7/7, indicating very high risk and complexity. The ETP is not UCITS compliant and is structured as a debt security with collateral backing. The product is intended for sophisticated investors who understand leverage, daily rebalancing, and compounding risks, and it is explicitly stated that it is not simple and may be difficult to understand. The presence of leverage, daily compounding, and the ETP legal structure are the main drivers of complexity under MiFID II, despite the absence of derivatives or swaps. The PRIIPs KID and factsheet confirm no swap usage and physical replication, but leverage and compounding effects are key complexity factors. The product also carries counterparty risk related to the issuer and collateral but no direct derivative counterparty risk. The recommended holding period is 1 day, emphasizing the complexity and risk of holding longer. Overall, the leverage and compounding effects, combined with the ETP structure and high risk profile, classify this product as complex under MiFID II."
}